- Spot gold breaks through $4,170 per ounce
- US Stock Market Movement: Bristol Myers Squibb Surges on October 12 Due to Dual Phase III Success and Innovative Drug Pipeline
- [US Stock Movement] First Tracks surged on October 12: ANB033 positive + celiac disease
- BUZZ-TD Cowen initiates coverage on Brown & Brown with a "Buy" rating, shares rise accordingly
- UBS identifies the next main theme for AI trading: electricity, data centers, and key resources
- "The Big Short" Burry shifts to Nasdaq and semiconductor ETF put options, warning of a market peak within 9 months
- 【US stocks volatility】Salesforce surged on October 12: Rating upgrade + AI product launch + enterprise CRM
- US lithium-ion battery maker Enovix's Q3 prelim revenue beats estimates, helped by defense demand
- TRANSDIGM GROUP INCORPORATED <TDG.N>: GOLDMAN SACHS CUTS TARGET PRICE TO $1745 FROM $1972
- L3HARRIS TECHNOLOGIES, INC. <LHX.N>: GOLDMAN SACHS CUTS TARGET PRICE TO $361 FROM $405
- WHIRLPOOL CORPORATION <WHR.N>: GOLDMAN SACHS CUTS TARGET PRICE TO $41 FROM $48
- Zenas BioPharma Reports New Obexelimab Data in IgG4-Related Disease
- UBS Initiates Coverage on Protagonist Therapeutics With Buy Rating, $184 Price Target
- --DA Davidson Initiates American Savings Bank at Buy With $20 Price Target
- --UBS Initiates Coverage on Nektar Therapeutics With Neutral Rating, $53 Price Target
- --UBS Initiates Coverage on Mineralys Therapeutics With Neutral Rating, $29 Price Target
- Iridex Says Glaucoma Therapy Lowers Eye Pressure, Reduces Medication Use
- Harmony Biosciences Promotes COO Peter Anastasiou to President, CEO
- TACTILE SYSTEMS TECHNOLOGY, INC. <TCMD.O>: BTIG CUTS TARGET PRICE TO $35 FROM $39
- OWENS CORNING <OC.N>: GOLDMAN SACHS CUTS TARGET PRICE TO $128 FROM $169
- BUZZ - Bank of America double upgrades Salesforce to "Buy"; stock rises
- FRONTDOOR INC <FTDR.O>: GOLDMAN SACHS CUTS TARGET PRICE TO $81 FROM $91
- STRYKER CORPORATION <SYK.N>: BTIG CUTS TARGET PRICE TO $316 FROM $358
- ING Bank: French fiscal concerns may weigh on the euro, while the Federal Reserve’s hawkish stance supports the dollar
- MERITAGE HOMES CORP <MTH.N>: GOLDMAN SACHS CUTS TARGET PRICE TO $82 FROM $93
- SHOULDER INNOVATIONS, INC. <SI.N>: BTIG RAISES TARGET PRICE TO $27 FROM $26
- European natural gas rises to a one-month high as cooling temperatures test demand
- INSTALLED BUILDING PRODUCTS, INC. <IBP.N>: GOLDMAN SACHS CUTS TARGET PRICE TO $257 FROM $297
- Gold prices surge then retreat as US dollar and inflation data dominate the market
- KRATOS DEFENSE & SECURITY SOLUTIONS, INC. <KTOS.O>: GOLDMAN SACHS CUTS TARGET PRICE TO $77 FROM $88
- Morgan Stanley's Wilson: The bond market is already “raising rates” for the Fed, two major signals needed for a US stock rebound
- TRONOX HOLDINGS PLC <TROX.N>: GOLDMAN SACHS CUTS TARGET PRICE TO $4 FROM $6.50
- Will the pessimistic outlook for US Treasuries change after the midterm elections? [Dapeng Talk 7]
- GLAUKOS CORPORATION <GKOS.N>: BTIG RAISES TARGET PRICE TO $205 FROM $202
- Update: Morgan Stanley Upgrades SLM to Overweight From Equalweight, Adjusts PT to $30 From $28
- --B. Riley Cuts Price Target on Byrna Technologies to $11 From $12, Keeps Buy Rating
- GE HEALTHCARE <GEHC.O>: BTIG CUTS TARGET PRICE TO $75 FROM $79
- DEXCOM INC <DXCM.O>: BTIG RAISES TARGET PRICE TO $96 FROM $90
- IDEXX LABORATORIES, INC. <IDXX.O>: KEYBANC INITIATES COVERAGE WITH SECTOR WEIGHT RATING
- CARLSMED, INC. <CARL.O>: BTIG RAISES TARGET PRICE TO $24 FROM $23
- ATRICURE, INC. : BTIG RAISES TARGET PRICE TO $63 FROM $55
- PP Presisi corrects June 2026 public offering proceeds report, shows IDR 61.34 billion remaining funds
- Bank of Ireland: September card spending rises 2% y/y as concerts drive local spikes
- TORM raises FY 2026 outlook, sees TCE USD 1.7 billion-1.9 billion
- -- Earnings Flash (PEP) PepsiCo, Inc. Posts Q3 Adjusted EPS $2.34 per Share, vs. FactSet Est of $2.29
- Thule Group to present Q3 2026 report in webcast and conference call
- Enovix Q3’26 operating loss widens to $39.3 million; revenue rises 38% year/year to $11 million
- Watsco completes acquisition of Granite Group
- Invoicery Group September net sales rise 0.3% to 171.9 MSEK
- Streamex adds CNB Custody as qualified custodian for GLDY shares
- TG Therapeutics reports five-year analysis shows BRIUMVI lowers disability progression risk vs Roche’s Ocrevus and Novartis’ Kesimpta
- Watsco Completes Acquisition Of The Granite Group, Distributor Of Plumbing And HVAC Products With $500 Million In Revenue Throughout The Northeast >WSO
- IonQ to Reportedly Buy Elisity for Up to $1.3 Billion
- SKYDANCE <SKYD.N>: STONEX CUTS TARGET PRICE TO $11 FROM $16
- --Piper Sandler Initiates American Savings Bank at Overweight
- Deutsche Bank raises Microsoft target price to $600
- SKYDANCE <SKYD.N>: STONEX CUTS TARGET PRICE TO $11 FROM $16
- --Keefe, Bruyette & Woods Initiates American Savings Bank at Market Perform With $19 Price Target
- --Hovde Group Initiates Coverage on First Financial With Outperform Rating, $85 Price Target
- --Hovde Group Initiates Coverage on Chemung Financial With Market Perform Rating
- --IonQ to Reportedly Buy Elisity for Up to $1.3 Billion
- Bristol-Myers Squibb Says Phase-3 Idiopathic Pulmonary Fibrosis Trial Met Primary Endpoint
- Bausch + Lomb Names Thomas Appio Interim CEO; Expects to Raise 2026 Guidance
- Market Chatter: ASML to Raise Prices of Spare Parts Supplied to South Korea From 2027
- TRADEWEB MARKETS INC <TW.O>: TD COWEN RAISES TARGET PRICE TO $107 FROM $98
- T. ROWE PRICE GROUP, INC. <TROW.O>: TD COWEN CUTS TARGET PRICE TO $109 FROM $110
- TPG INC <TPG.O>: TD COWEN CUTS TARGET PRICE TO $60 FROM $64
- Polar Power Names Chris Mayer Co-Chief Executive
- Keefe Bruyette & Woods Upgrades Brown & Brown to Outperform, $77 Price Target
- BNP Paribas Upgrades Dr. Reddy's Laboratories to Outperform Neutral, $14.80 Price Target
- STIFEL FINANCIAL CORP. <SF.N>: TD COWEN CUTS TARGET PRICE TO $78 FROM $84
- Reshaping Keynesian Thought Recognized with Nobel Prize! American economists Hall and Woodford reveal the underlying logic of consumption decisions and central bank policies
- THE CHARLES SCHWAB CORPORATION <SCHW.N>: TD COWEN RAISES TARGET PRICE TO $129 FROM $128
- Phillip Securities Downgrades Palantir Technologies to Neutral From Buy, Price Target is $215
- Top Premarket Decliners
- BLUE OWL CAPITAL INC. <OWL.N>: TD COWEN RAISES TARGET PRICE TO $16 FROM $15
- NASDAQ INC <NDAQ.O>: TD COWEN CUTS TARGET PRICE TO $107 FROM $108
- C.H. ROBINSON WORLDWIDE, INC. <CHRW.O>: DEUTSCHE BANK CUTS TO HOLD FROM BUY; CUTS TARGET PRICE TO $153 FROM $220
- LPL FINANCIAL HOLDINGS INC. <LPLA.O>: TD COWEN RAISES TARGET PRICE TO $380 FROM $377
- Updated: Bristol Myers Squibb’s drug improved lung function in late-stage clinical trials
- KKR <KKR.N>: TD COWEN CUTS TARGET PRICE TO $103 FROM $118
- INVESCO LTD <IVZ.N>: TD COWEN CUTS TARGET PRICE TO $38 FROM $39
- Seaport Global Upgrades Mattel to Buy From Neutral, Assigns $20 Price Target
- MATTEL INC <MAT.O>: SEAPORT RESEARCH PARTNERS RAISES TO BUY FROM NEUTRAL
- FEDERATED HERMES INC <FHI.N>: TD COWEN CUTS TARGET PRICE TO $56 FROM $60
- BUILDERS FIRSTSOURCE INC <BLDR.N>: BMO CUTS TARGET PRICE TO $68 FROM $80
- UFP INDUSTRIES, INC. <UFPI.O>: BMO CUTS TARGET PRICE TO $104 FROM $108
- CARLYLE GROUP INC <CG.O>: TD COWEN CUTS TARGET PRICE TO $42 FROM $54
- CBOE GLOBAL MARKETS, INC. <CBOE.Z>: TD COWEN RAISES TARGET PRICE TO $342 FROM $334
- Top Premarket Gainers
- BLACKSTONE <BX.N>: TD COWEN CUTS TARGET PRICE TO $144 FROM $154
- MASCO CORPORATION <MAS.N>: BMO CUTS TARGET PRICE TO $75 FROM $77
- BLACKROCK <BLK.N>: TD COWEN RAISES TARGET PRICE TO $1,212 FROM $1,190
- FRANKLIN TEMPLETON, INC. <BEN.N>: TD COWEN CUTS TARGET PRICE TO $38 FROM $40
- FORTUNE BRANDS INNOVATIONS, INC. <FBIN.N>: BMO CUTS TARGET PRICE TO $48 FROM $53
- Acquinox Capital says voluntary AI “pacing” shifts frontier-lab investment case to enterprise adoption, margins
- BROOKFIELD BUSINESS HOLDINGS CORP <BBUC.N>: TD COWEN CUTS TARGET PRICE TO $29 FROM $32
- ARES MANAGEMENT CORPORATION : TD COWEN CUTS TARGET PRICE TO $159 FROM $163
- COMMUNITY FINANCIAL SYSTEM INC <CBU.N>: D.A. DAVIDSON CUTS TARGET PRICE TO $69 FROM $70
- GREIF INC <GEF.N>: TRUIST SECURITIES CUTS TARGET PRICE TO $94 FROM $97
